Vect-Horus renforce son conseil d’administration avec la nomination de Jean-Christophe Dantonel
14. November 2024 03:00 ET
|
Vect-Horus
COMMUNIQUÉ DE PRESSE Professionnel expérimenté dans le secteur de la santé et scientifique accompli Jean-Christophe Dantonel apporte à...
Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
14. November 2024 03:00 ET
|
Vect-Horus
PRESS RELEASE Accomplished research scientist and business professional Brings important skills for both clinical and business...
Vect-Horus participera à une table ronde lors de la conférence Viva Technology
07. Mai 2024 03:00 ET
|
Vect-Horus
Marseille, France, 7 Mai - VECT-HORUS, l'entreprise de biotechnologie qui conçoit et développe des molécules « vecteurs » qui facilitent l’adressage de molécules thérapeutiques ou d’agents d’imagerie...
Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
07. Mai 2024 03:00 ET
|
Vect-Horus
Marseille, France, May 7th - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging...
Une nouvelle publication de Vect-Horus dans Pharmaceutics démontre comment les vecteurs peuvent améliorer l’adressage de molécules thérapeutiques vers des organes et tumeurs
22. April 2024 09:56 ET
|
Vect-Horus
Marseille, France, 22Avril - VECT-HORUS, l'entreprise de biotechnologie qui conçoit et développe des molécules « vecteurs » qui facilitent l’adressage de molécules thérapeutiques ou d’agents...
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
22. April 2024 09:56 ET
|
Vect-Horus
Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging...
VECT-HORUS: Two new patents protecting VECTrans(R) technology issued in several major countries
02. November 2015 05:31 ET
|
VECT-HORUS
MARSEILLE, France, Nov. 2, 2015 (GLOBE NEWSWIRE) -- VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs,...
Neurotensin, vectorised by Vect-Horus, is the first drug-candidate in neuroprotective hypothermia
19. März 2015 06:30 ET
|
VECT-HORUS
MARSEILLE, France, March 19, 2015 (GLOBE NEWSWIRE) -- VECT-HORUS is a biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents, notably in...
VECT-HORUS announces the signing of a scientific collaboration agreement with SANOFI
19. Januar 2015 01:38 ET
|
VECT-HORUS
VECT-HORUS announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
MARSEILLE, France, Jan. 19, 2015 (GLOBE NEWSWIRE) -- VECT-HORUS, a...
VECT-HORUS: new equity issue of 1.5 MEU to finance the preclinical development of its first vectorized product
15. Dezember 2014 01:34 ET
|
VECT-HORUS
MARSEILLE, France, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Vect-Horus, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in...